Loss-of-function mutations in APOC3 and risk of ischemic vascular disease.

By A. Jørgensen, R. Frikke-Schmidt, Børge G. Nordestgaard, A. Tybjærg-Hansen. New England Journal of Medicine, 2014

886 citations recorded by the source corpus.

Subfields: Cell Biology, Endocrinology, Diabetes and Metabolism, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/55f5e169d6f4d9a568cca4bbafe0790022e8bc16

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cell Biology

1. Børge G. Nordestgaard

In Endocrinology, Diabetes and Metabolism

1. I. Graham
2. Børge G. Nordestgaard
3. Ronald M. Krauss

In Pulmonary and Respiratory Medicine

1. I. Graham
2. Børge G. Nordestgaard
3. Sekar Kathiresan

Citations in the corpus

• 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. (2016, background): “67,122 Table 7 lists recommendations for lipid analyses in CVD risk estimation, Table 8 lists recommendations for lipid analyses for characterization of dyslipidaemias before treatment and Table 9 lists recommendations for lipid analyses as treatment targets in the prevention of CVD. Apo ¼ apolipopr”
• Human knockouts and phenotypic analysis in a cohort with a high rate of consanguinity (2017, positive): “We and others recently reported that heterozygous APOC3 pLoF mutations lower plasma triglycerides and reduce risk for coronary heart disease 4,5,25 ; there is now substantial interest in APOC3 as a therapeutic target 26–28 .”
• Triglyceride-Rich Lipoproteins and Atherosclerotic Cardiovascular Disease: New Insights From Epidemiology, Genetics, and Biology. (2016, positive): “of ASCVD in individuals from the Copenhagen general population.(72) In a parallel study published back-to-back and including 18 different cohorts combined, APOC3 loss-of-function”